Luput Cristian 4

What Happened

• Cristian Luput, a director of MAIA Biotechnology, was granted a derivative award on 2026-03-31 representing the right to acquire 28,556 shares of MAIA common stock. The reported acquisition value is $0.00 (no cash paid at grant). According to the filing, the options vest 100% on the grant date and are exercisable immediately.

Key Details

• Transaction date and type: 2026-03-31 — Grant/Award of derivative securities (Form 4 code A).
• Reported price: $0.00 (the filing shows no cash paid at grant; the grant is an option/award rather than an open‑market purchase).
• Vesting/exercise: Per the footnote, options vest 100% on grant and are exercisable as of the grant date.
• Plan: Granted under MAIA Biotechnology, Inc.’s 2021 Equity Incentive Plan (footnote F1).
• Shares owned after transaction: Not specified in the provided summary of the filing — see the full Form 4 for total beneficial ownership.
• Filing timeliness: Transaction date 2026-03-31; Form 4 filed 2026-04-02 — appears timely (Form 4 is generally due within two business days).

Context

• This is an equity incentive award (options) rather than an outright purchase or sale. Options give the holder the right to buy shares in the future (upon exercise) and only translate to share ownership if/when exercised. Immediate vesting and exercisability mean Luput can exercise the options right away, but exercising would typically require paying any exercise price (not specified here) and may trigger tax withholding. For full details (exercise price, total ownership post‑grant), check the complete Form 4 filing.